Navidea Biopharma (NYSE: NAVB) reported Q2 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $261 thousand versus the consensus estimate of $600 thousand.

Navidea ended the second quarter of 2021 with $7.1 million in cash and cash equivalents.

“The Company is prepared and looking forward to our meeting with the U.S. Food and Drug Administration (“FDA”) on September 1,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea. “We remain laser focused on a positive meeting and a successful launch to the NAV3-33 trial. Navidea is also extremely excited to now have a full 7-member board with the appointments of Amit Bhalla, Alex Cappello and John K. Scott, Jr. to the board.”

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.